Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.63 |
| ▸ | PI4KA | P42356 | 3/20 | 0.58 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.58 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.58 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.58 |
| ▸ | AHCY | P23526 | 5/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27432827 | 0.88 | ADORA2A (0.62) | ALDH1A1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL7396925 | 0.87 | ALDH1A1 (0.70) | ALDH1A1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL6045563 | 0.84 | ADORA2A (0.61) | ALDH1A1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL6532875 | 0.84 | ALDH1A1 (0.73) | ALDH1A1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL2049965 | 0.82 | ALDH1A1 (1.00) | ALDH1A1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL10683911 | 0.82 | ALDH1A1 (0.75) | ALDH1A1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL2270408 | 0.82 | ALDH1A1 (0.75) | ALDH1A1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL2049963 | 0.82 | ALDH1A1 (1.00) | ALDH1A1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL2049962 | 0.82 | ALDH1A1 (1.00) | ALDH1A1ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL13394189 | 0.81 | ADORA2A (0.76) | ALDH1A1ADORA2AADORA1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252774-A1 | Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases | NEW JERSEY, UNIVERSITY OF MEDICINE AND DENTISTRY OF | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252774-A1 | Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases | ADCY5, ADCY6, ADCY2 | ALDH1A1 1333/4885ADORA2A 303/4885ADORA1 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.